Buscar | Meisterbook

agregó una foto Health

2026-07-17 10:19:40 -

Neuroblastoma Cancer Market: How Is GD2-Targeted Immunotherapy Becoming the Fastest-Growing Therapeutic Paradigm?

GD2-targeted immunotherapy for neuroblastoma — the monoclonal antibody and CAR-T cell therapies targeting the disialoganglioside GD2 antigen uniformly expressed on neuroblastoma cells, transforming high-risk disease outcomes from <50% to >70% long-term survival representing the fastest-growing therapeutic paradigm in the global neuroblastoma cancer market — creates the most...

0 Commentarios 0 Acciones 3 Views 0 Vista previa